AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01015131 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET/CT Imaging
Description: Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
Study NCT04480424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAMUNEX-C
Description: Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
Study NCT04480424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: SMT per local policies or guidelines.
Study NCT04480424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: SMT per local policies or guidelines.
Study NCT01857583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg DU-176b
Study NCT01857583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30mg DU-176b
Study NCT01857583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Study NCT02211638 — intervention group
Intervention type: DRUG
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil tablet
Study NCT02782923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
Study NCT02782923 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STISIM driving simulator
Description: This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
Study NCT04382755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zilucoplan®
Description: 14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
Study NCT04382755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
Study NCT02900560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC-486
Description: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
Study NCT03752905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline control
Study NCT02900560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 21 days
Study NCT00854659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-102
Description: BID tablets, 7 days of treatment
Study NCT00854659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID tablets, 7 days of treatment
Study NCT03625063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training group
Description: All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
Study NCT03625063 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control training group
Description: All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
Study NCT05026294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercises
Description: Exercises for strength and flexibility
Study NCT05026294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises for flat feet rehabilitation
Description: Exercises for intrinsic muscles strength
Study NCT03994172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriparatide or human parathyroid hormone (PTH) 1-34
Description: Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide or human parathyroid hormone (PTH) 1-34
Description: Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium citrate tablet
Description: Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium citrate tablet
Description: Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
Study NCT03994172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
Study NCT00716443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)
Description: Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
Study NCT00716443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine 20% / lidocaine 6% / tetracaine 4% ointment
Description: apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
Study NCT01997983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 Gel mixed with Botox (BTX)
Description: TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
Study NCT01591980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
Study NCT01591980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
Study NCT00836849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg Tablets
Description: 1 x 100 mg, single-dose fed
Study NCT00836849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg Tablets
Description: 1 x 100 mg, single-dose fed
Study NCT01591980 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Identical placebo capsules will be administered in the same way.
Study NCT04616586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 11 mg/kg IV administered over 1 hour
Study NCT04616586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: IV administered over 1 hour
Study NCT01886664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Study NCT01886664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study NCT05385562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate
Description: formulated with sodium hyaluronate and chondroitin sulfate
Study NCT05385562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide alone
Description: Triamcinolone Acetonide alone
Study NCT01420133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regimen
Description: regimen normal in salt and sugar
Study NCT01420133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard regimen
Description: with diet low in salt and sugar
Study NCT01409317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation
Description: DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
Study NCT01409317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
Study NCT02585544 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: day-care surgery
Description: day-care surgery
Study NCT00035893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly I-poly C12U
Description: 200-400 mg IV infusions 2x/week for 64 weeks
Study NCT03876587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate combine with Docetaxel
Description: Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
Study NCT00353977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-CMV (vCP260)
Description: ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)
Study NCT02886104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRLM resection group
Description: Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
Study NCT02886104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRLM ablation group
Description: Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
Study NCT01590329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Momelan Technologies Epidermal Graft Harvesting System
Description: The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
Study NCT04721314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustment of lower rate limit
Description: Patients with preserved ejection fraction (EF >50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
Study NCT04721314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of lower rate limit
Description: Lower rate limit will be maintained at 60 beats-per-minute
Study NCT01937312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
Study NCT01937312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT01937312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue
Study NCT01937312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prostaglandin analogue
Study NCT00497224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
Study NCT02220374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Finger Tape
Description: Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
Study NCT02284724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Study NCT02284724 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sham Needling
Study NCT01531725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT03002506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
Study NCT06509061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Self-Definition
Description: 6 week behavioural change program designed to increase PASD and PA
Study NCT06509061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 6 week program designed to as an attention control, delivering content on general health behaviour.
Study NCT02757547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation - Placebo Arm
Description: Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
Study NCT02757547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation - Active Arm
Description: Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
Study NCT04915521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block (ESPB) group
Description: An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure.
Study NCT01939262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limitation of Animal Fat and Protein in the Diet
Description: Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
Study NCT01939262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants assigned to the control group will be instructed to follow their usual diets.
Study NCT03215277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: One bimekizumab dose will be administered.